research use only
Cat.No.S4428
| Related Targets | Integrase Bacterial Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite HIV HCV Protease |
|---|---|
| Other Reverse Transcriptase Inhibitors | Dapivirine (TMC120) Fangchinoline 3'-Fluoro-3'-deoxythymidine (Alovudine) Salicylanilide Bifendate Ulonivirine Lersivirine (UK-453061) 4-Chloro-2-(trifluoroacetyl)aniline hydrochloride |
|
In vitro |
DMSO
: 100 mg/mL
(168.76 mM)
Ethanol : 100 mg/mL Water : 10 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 592.54 | Formula | C25H33N6O9P |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 379270-38-9 | -- | Storage of Stock Solutions |
|
|
| Synonyms | TAF fumarate, GS-7340 fumarate | Smiles | CC(C)OC(=O)C(C)N[P](=O)(COC(C)C[N]1C=NC2=C(N)N=CN=C12)OC3=CC=CC=C3.OC(=O)\C=C\C(O)=O | ||
| Targets/IC50/Ki |
reverse transcriptase
|
References |
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05652478 | Not yet recruiting | Healthy Volunteer|Weight Gain|Metabolic Effects|Integrase Strand Transfer Inhibitors |
National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
May 15 2024 | Phase 2 |
| NCT06104306 | Recruiting | HIV-1-infection |
Gilead Sciences |
December 13 2023 | Phase 4 |
| NCT05583006 | Recruiting | Patient Satisfaction|Drug Adherence|Efficacy Self|Safety Issues |
Taichung Veterans General Hospital|Institute of Adherence to Medication |
November 6 2023 | -- |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.